Pharmaceutical company to pay $96 million to settle claims of promoting unapproved use of drug for dementia...
By
Lois A. Bowers
Sep 27, 2019
Pharmaceutical company Avanir has agreed to pay $96 million to resolve federal False Claims Act allegations that it paid kickbacks and marketed the drug Nuedexta in long-term care communities for the off-label...
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Brain imaging company teases tech that will analyze side effects of new dementia drugs
By
Aaron Dorman
Nov 28, 2023
AI-enabled brain imaging technology will be launched next year to evaluate the side effects of new Alzheimer’s and dementia drugs.
Dementia to cost nation $321 billion this year, Alzheimer’s Association says
By
Kimberly Bonvissuto
Mar 16, 2022
This year, Alzheimer’s and other dementias will cost the nation $321 billion, increasing to $1 trillion by 2050, according to a report released Tuesday by the Alzheimer’s Association.
NIH requests additional $321M for Alzheimer’s, dementia research
By
Kimberly Bonvissuto
Aug 02, 2022
The National Institutes of Health has requested an additional $321 million in fiscal year 2024 for research into Alzheimer’s and other dementias.
Industry advocates join coalition to support federal bill requiring use of Alzheimer’s detection tools
By
Kimberly Bonvissuto
Oct 04, 2023
A bipartisan bill requiring the use of cognitive impairment detection tools in the early detection of Alzheimer’s disease and related dementias has the support of the senior living industry.
Study maps ‘home time’ for Medicare beneficiaries in assisted living communities
By
Kristen Fischer
Dec 21, 2023
A new study gives more insight into how much time older people in assisted living spend in and out of the setting.
3 new dementia studies of note
Oct 27, 2015
New research quantifies costs associated with dementia care compared with other diseases and offers a little good news for those with Lewy body dementia or Alzheimer’s disease.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.